Joint Formulary & PAD

Domperidone - Nausea and vomiting (pregnancy)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Oral suspension
  • Tablets
Associated Icons :
Restrictions / Comments :
Important
2nd line treatment option but should not be prescribed for longer than 7 days.

MHRA drug safety update (December 2019- Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents : https://www.gov.uk/drug-safety-update/domperidone-for-nausea-and-vomiting-lack-of-efficacy-in-children-reminder-of-contraindications-in-adults-and-adolescents

PAD Profile

ChemicalSubstance :
Domperidone
Indication :
Nausea and vomiting (pregnancy)
Group Name :
Keywords :
morning sickness, emesis, anti-emetic
Brand Names Include :
Motilium
Important Information :
Safety alert and cardiac side-effects.
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
2

Committee Recommendations (1)

The Surrey Heartlands APC agreed a traffic light status and place in therapy for drugs used to treat nausea and vomiting in pregnancy.

Visit  the Guideline Profile page for a full list of these drugs and to access the CKS guidelines for nasea & vomiting and pregnancy and the BUMPS website (Best Use of Medicines in Pregnancy).